Derek Lowe

Derek Lowe is a medicinal chemist working on preclinical drug discovery in the pharmaceutical industry. Lowe has published a blog about this field, "In the Pipeline", since 2002 and is a columnist for the Royal Society of Chemistry's Chemistry World.Lowe (born in Harrisburg, Arkansas) got his BA from Hendrix College and his PhD in organic chemistry from Duke University on synthesis of natural products, before spending time in Germany on a Humboldt Fellowship.Lowe was the one of the first people to blog from inside the pharmaceutical industry (he talked to his supervisor and the company legal department before starting), and one of the first science bloggers. By 2006, his blog had between 3,000 and 4,000 visitors per day during the workweek; he covered business matters, trends and issues in medicinal chemistry, and legal matters like patent law and regulation. At that time he was working at a pharmaceutical chemistry doing hit to lead medical chemistry work. As of 2010 his blog received between 15,000 and 20,000 page views on a typical weekday. His response to a 2013 article in Buzzfeed that propagated chemophobia was widely cited.He serves on the editorial board of ACS Medicinal Chemistry Letters and on the advisory board of Chemical & Engineering News.As of 2018 he was working at Novartis; formerly he had worked for 10 years at Vertex, 9 years at Bayer, and 8 years at Schering-Plough. Book Lowe, Derek B. (2016). The Chemistry Book: From Gunpowder to Graphene, 250 Milestones in the History of Chemistry. Sterling. ISBN 9781454911807.Selected scientific papersGreenlee, W; Clader, J; et al. (April 2001). "Muscarinic agonists and antagonists in the treatment of Alzheimer's disease". Farmaco (Societa Chimica Italiana : 1989). 56 (4): 247–50. PMID 11421251. Lowe, DB; Magnuson, S; et al. (21 June 2004). "In vitro SAR of (5-(2H)-isoxazolonyl) ureas, potent inhibitors of hormone-sensitive lipase". Bioorganic & Medicinal Chemistry Letters. 14 (12): 3155–9. doi:10.1016/j.bmcl.